Efficacy and Safety of Anti-PD-(L)1 Treatments: A Systematic Review and Meta-analysis of Asian vs Non-Asian Patients With Esophageal Squamous Cell Carcinoma
This meta-analysis indicates that there is no significant difference in OS between Asian and non-Asian ESCC patients receiving 1L or 2L anti-PD-(L)1 treatment. Results may support regulatory and health technology assessment decision making. In addition, they may encourage wider guideline consideration for anti-PD-(L)1s.
Authors
- Sylvie Lorenzen
- Julia Kretz (ORCID: https://orcid.org/0000-0002-5408-4583)
- Ken Kato
- Jaffer A. Ajani (ORCID: https://orcid.org/0000-0001-9946-0629)
- Ronan J. Kelly (ORCID: https://orcid.org/0000-0002-6446-2103)
- Lin Zhan (ORCID: https://orcid.org/0000-0001-7690-7782)
- Filippo Pietrantonio (ORCID: https://orcid.org/0000-0002-8530-8420)
- Alysha Kadva (ORCID: https://orcid.org/0000-0002-2637-8373)
- Xiaowei Zhang (ORCID: https://orcid.org/0000-0002-7095-5326)
Institutions
- Roche (Switzerland) (CH)
- Statistics Austria (AT)
- The University of Texas MD Anderson Cancer Center (US)
- Baylor University Medical Center (US)
- TUM Klinikum (DE)
- National Cancer Centre Japan (JP)
- National Cancer Center (US)
- Samsung (United States) (US)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
Publication Details
- Journal
- Gastro Hep Advances
- Published
- 2025-11-08
- DOI
- https://doi.org/10.1016/j.gastha.2025.100843
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00